Liver cancer drug safety checked in 263 patients
NCT ID NCT05100082
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study looked at the safety of the drug Cabometyx in 263 Japanese people with a type of liver cancer called hepatocellular carcinoma. Participants took the drug as part of their normal care, and doctors watched for side effects over 12 months. The main goal was to see how often serious side effects or liver problems occurred. This was an observational study, meaning the sponsor did not control treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.